Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of UBT251 injection in obese participants with moderate-to-severe obstructive sleep apnea not using positive airway pressure therapy
CTR20263873Phase 3Active
- Sponsor
- The United Laboratories International Holdings
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) and obesity comparing UBT251 with Placebo (2 arms). Primary endpoint: Change from baseline in apnea-hypopnea index. Started Oct 2026; status: active.
02
Drugs
UBT251
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on CTR20263873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263873.